Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
Oklahoma Medical Research Foundation | OMRF
OMRF is an independent, nonprofit biomedical research institute dedicated to discoveries that make a difference.
